Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Biochim Biophys Acta. 2010 Apr 28;1803(7):872–880. doi: 10.1016/j.bbamcr.2010.04.007

Figure 6.

Figure 6

Western blot analysis of gp-91 in H9c2 cardiomyoblasts transfected with or without gp-91 siRNA. (A): H9c2 cardiomyoblast were transfected with gp-91 (500 nmol/L) or scrambled siRNA (500 nmol/L) for 24 h to prepare protein lysates and following immunoblotting assay. (B) The LDH release of H9c2 myocytes in culture medium at the end of reperfusion (n=4/group). (C): Cell viability was measured using the MTT cell viability assay (n=4/group). H9c2 cardiomyoblast cells were exposed to simulated ischemia (KCN and 2-deoxy-D-glucose) and description of simulated ischemia is provided under METHODS. HDAC inhibitor, trichostatin A (50 nmol/L) was maintained in culture medium. Gp-91 and negative control siRNA transfections are described as under METHODS. SI: simulated ischemia. LDH: lactate dehydrogenase. Results are expressed as means ± SE and the values expressed as percentages of control values. *P < 0.05.